Format

Send to

Choose Destination
Anticancer Res. 2002 May-Jun;22(3):1925-8.

The correlation between immunohistochemically-detected markers of angiogenesis and serum vascular endothelial growth factor in patients with breast cancer.

Author information

1
Department of Obstetrics and Gynecology, Martin-Luther-University Halle-Wittenberg, Halle, Germany. tilmann.lantzsch@medizin.uni-halle.de

Abstract

BACKGROUND:

As angiogenesis is known to be a crucial factor in breast cancer growth, numerous studies have examined angiogenic markers in breast cancer. Their definite role, however, has not been fully elucidated.

MATERIALS AND METHODS:

We investigated intratumoral microvessel density (MVD), Vascular Endothelial Growth Factor (VEGF) and its receptor flk-1, and serum VEGF in 46 patients with breast cancer prior to surgery.

RESULTS:

Median serum VEGF in patients with breast cancer was 257.5 pg/mL (range, 21.9 to 899.6). Serum VEGF showed a significant correlation with tumor stage, but not with lymph node involvement, histological grade, estrogen and progesterone receptor status. Increased MVD was associated with advanced tumor stage (p=0.05) and high tumor grade (p<0.001). A linear significant correlation between elevated serum VEGF and increased MVD was ascertained (p=0.02).

CONCLUSION:

Our results suggested that angiogenesis as reflected by immunohistochemically-detected MVD and serum VEGF, is involved in breast cancer growth and lymphatic spread.

PMID:
12168895
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center